Catalog No.: PC-24977Not For Human Use, Lab Use Only.
Icotrokinra (JNJ-77242113, PN-21235) is a highly potent, selective peptide antagonist targeting the IL-23 receptor with KD of 7.1 pM, potently and selectively inhibits proximal IL-23 signaling (IC50=5.6 pM) without impacting IL-12 signaling.
Icotrokinra (JNJ-77242113, PN-21235) is a highly potent, selective peptide antagonist targeting the IL-23 receptor with KD of 7.1 pM, potently and selectively inhibits proximal IL-23 signaling (IC50=5.6 pM) without impacting IL-12 signaling.
JNJ-77242113 inhibited IL-23–induced interferon (IFN)γ production in NK cells, and in blood from healthy donors and psoriasis patients with IC50 of 18.4, 11 and 9 pM, respectively).
JNJ-77242113 attenuated disease parameters at doses ≥ 0.3 mg/kg/day in rat trinitrobenzene sulfonic acid-induced colitis model. JNJ-77242113 exhibits dose-dependent inhibition of ex vivo IL-23–stimulated IL-17A production in blood from rats.
JNJ-77242113 inhibited IL-23–induced skin thickening and IL-17A, -17F and -22 gene induction in IL-23–induced rat skin inflammation model.
